- At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.
- navify Algorithm Suite is a secure digital ecosystem that links physicians easily to a range of medical algorithms from Roche and its innovation partners without the hurdle of integrating multiple algorithm providers.
- First available medical algorithms focus on identifying patients at risk for some liver and colon cancers. Medical algorithms for cardiac, lung and other disease states are in the pipeline.
Roche (SIX: RO, ROG; OTCQX: RHHBY) introduces its navify® Algorithm Suite, a single platform hosting a library of digital medical algorithms that generate patient-centric insights and can aid earlier diagnosis of cancer and other conditions per intended use, at the HIMSS Global Conference in Chicago, USA, from April 17- 21, 2023.
Physicians use medical algorithms, evidence-based decision-making tools, in the diagnosis, treatment and monitoring of patients to optimise care, increase early diagnosis and adhere to guidelines. Use of real-time clinical decision support is associated with adherence to evidence-based guidelines and as an aid in screening of colorectal cancer.2,3
“As healthcare data is set to grow,4 digital medical algorithms can generate actionable insights which physicians can use to start delivering on the promise of personalised healthcare, “ said Moritz Hartmann, Global Head of Roche Information Solutions at Roche Diagnostics. "With navify Algorithm Suite, clinicians can easily order the medical algorithms they need from Roche and other providers to get enhanced insights that improve patient care."
navify Algorithm Suite offers labs and hospitals one platform to connect easily to digital medical algorithms from a diverse range of innovators. This makes it easier for physicians to use and adopt the medical algorithms they need. Simultaneously, navify Algorithm Suite also offers universities and other providers of digital algorithms a direct channel to distribute their proven innovations to practising physicians in markets worldwide.
The platform is designed to be embedded in existing healthcare workflows and the lab or hospital information system (LIS/HIS) and/or the EHR/EMR (electronic health/medical record).
Designed for optimal information security management, navify Algorithm Suite complies with GDPR (General Data Protection Regulation) regulations in Europe as well as HIPAA (Health Insurance Portability and Accountability) in the USA.
The first algorithms in the navify Algorithm Suite focus on oncology:
- GAAD5 is intended as an aid in the diagnosis of early stage Hepatocellular Carcinoma (HCC) in patients with chronic liver disease. GAAD (an in-vitro diagnostic multivariate index assay) analyses gender, age in combination with results of two Roche assays Elecsys AFP and Elecsys PIVKA. This CE-marked algorithm6 may help physicians diagnose early stage hepatocellular carcinoma (HCC). Liver cancer is the sixth most common cancer worldwide7 and HCC is the most common form of liver cancer accounting for ~90% of cases.8 It is not available in the US.
- A pre-screening algorithm to identify at-risk healthy people for colorectal cancer. The ColonFlag algorithm from the Medial EarlySign company helps identify patients at high-risk for colon cancer by analysing age, sex, and a recent complete blood count (CBC).9 Colorectal cancer is the 3rd most common cancer worldwide with more than 1.9 million new cases of colorectal cancer in 2020.10 In the US, the ColonFlag algorithm is marketed as LGI-Flag™, as an indication for lower GI disorders.
Additional algorithms for oncology, cardiology and other diseases, such as lung and infectious diseases, are already in the pipeline. navify Algorithm Suite is currently available in Europe and Asia-Pacific.